Skip to main content

Advertisement

SpringerLink
Log in

MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival

  • original paper
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Background

MicroRNAs are small (18–22 nucleotides) noncoding RNAs involved in posttranscriptional modification of many target genes. One of these, microRNA-21 (miR-21), has been shown to play a role in multiple hematologic and solid organ malignancies. We sought to determine the expression pattern of miR-21 in pancreatic cancers and its impact on clinicopathologic characteristics.

Methods

Eighty resected pancreatic cancer specimens were microdissected and tissue microarrays (TMA) created in duplicate. TMAs were also created for benign pancreas (N = 12) and chronic pancreatitis (N = 45). In situ hybridization (ISH) was undertaken utilizing locked nucleic acid probes for miR-21. RNA U6 and scrambled RNA served as positive and negative control, respectively. ISH was scored as 0 (absent), 1+ (faint/focal expression), or 2+ (strong expression). Kaplan–Meier survival curves were constructed and compared by log-rank analysis.

Results

MiR-21 expression was demonstrated in 63 (79%) pancreatic cancers (1+ in 49, 2+ in 14) compared to one of 12 (8%, p < 0.0001) benign pancreas and 12/45 (27%, p < 0.0001) chronic pancreatitis. None of the benign tissues demonstrated strong miR-21 expression. Although miR-21 expression did not correlate with tumor size, differentiation, nodal status, or T stage, strong miR-21 expression was predictive of poorer outcome compared to absent or faint/focal miR-21 expression in patients with node-negative disease (median 27.7 months vs. 15.2, p = 0.037). Nodal status was also predictive of survival (p = 0.029).

Conclusions

MicroRNA-21 is significantly overexpressed in pancreatic cancers as detected by in situ hybridization. Its strong expression predicts limited survival in patients with node-negative disease and may be an important biologic marker for outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43–66.

    Article  PubMed  Google Scholar 

  2. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225(5):621–33. doi:10.1097/00000658-199705000-00018.

    Article  PubMed  CAS  Google Scholar 

  3. Bartel DP. MicroRNA’s: genomics biogenesis, mechanism, and function. Cell 2004;116:281–297. doi:10.1016/S0092-8674(04)00045-5.

    Article  PubMed  CAS  Google Scholar 

  4. Dillhoff M, Wojcik S, Bloomston M. MiRNAs in solid tumors. J Surg Res 2008;in press.

  5. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828–833. doi:10.1038/nature03552.

    Article  PubMed  CAS  Google Scholar 

  6. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297:1901–1908. doi:10.1001/jama.297.17.1901.

    Article  PubMed  CAS  Google Scholar 

  7. Lee E, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2006;120:1046–1054. doi:10.1002/ijc.22394.

    Article  CAS  Google Scholar 

  8. Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008;135(2):255–260. doi:10.1016/j.jtcvs.2007.08.055.

    Article  PubMed  CAS  Google Scholar 

  9. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189–198. doi:10.1016/j.ccr.2006.01.025.

    Article  PubMed  CAS  Google Scholar 

  10. Schetter A, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299(4):425–436. doi:10.1001/jama.299.4.425.

    Article  PubMed  CAS  Google Scholar 

  11. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65:6029–6033. doi:10.1158/0008-5472.CAN-05-0137.

    Article  PubMed  CAS  Google Scholar 

  12. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006;24(29):4677–4684. doi:10.1200/JCO.2005.05.5194.

    Article  PubMed  CAS  Google Scholar 

  13. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 2005;33(17):5394–5403. doi:10.1093/nar/gki863.

    Article  PubMed  CAS  Google Scholar 

  14. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006;66(15):7390–7394. doi:10.1158/0008-5472.CAN-06-0800.

    Article  PubMed  CAS  Google Scholar 

  15. Nuovo GJ. PCR In Situ Hybridization: Protocols and Applications. 3rd ed. Lippincott, New York: Williams and Wilkins, Raven, 1996.

    Google Scholar 

  16. Bloomston M, Bhardwaj A, Ellison EC, Frankel WL. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg 2006;23(1–2):74–79. doi:10.1159/000093497.

    Article  PubMed  CAS  Google Scholar 

  17. Lee EJ, Baek M, Gusev Y, Brackett DJ, Nuovo GJ, Schmittgen TD. Systematic evaluation of microRNA processing patterns in tissues, cells lines and tumors. RNA 2008;14(1):35–42. doi:10.1261/rna.804508.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Ohio State University, 410 W. 10th Ave., N924 Doan Hall, Columbus, OH, 43210, USA

    Mary Dillhoff & Mark Bloomston

  2. Department of Pathology, The Ohio State University, Columbus, OH, USA

    James Liu & Wendy Frankel

  3. Department of Molecular Virology, Immunology and Molecular Genetics, The Ohio State University, Columbus, OH, USA

    Carlo Croce

Authors
  1. Mary Dillhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wendy Frankel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlo Croce
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark Bloomston
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Bloomston.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dillhoff, M., Liu, J., Frankel, W. et al. MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival. J Gastrointest Surg 12, 2171–2176 (2008). https://doi.org/10.1007/s11605-008-0584-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-008-0584-x

Keywords

Search

Navigation